Organogenesis Holdings, Inc. (ORGO)
0.8101
-0.15
(-16.05%)
USD |
NASDAQ |
Nov 13, 16:00
0.8354
+0.03
(+3.12%)
After-Hours: 06:43
Organogenesis Holdings Net Income (Quarterly) : -29.63M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -29.63M |
| June 30, 2026 | -96.27M |
| March 31, 2026 | -53.16M |
| December 31, 2025 | 43.70M |
| September 30, 2025 | 21.57M |
| June 30, 2025 | -9.392M |
| March 31, 2025 | -18.84M |
| December 31, 2024 | 7.673M |
| September 30, 2024 | 12.33M |
| June 30, 2024 | -17.04M |
| March 31, 2024 | -2.10M |
| December 31, 2023 | -0.568M |
| September 30, 2023 | 3.167M |
| June 30, 2023 | 5.316M |
| March 31, 2023 | -2.969M |
| December 31, 2022 | 7.486M |
| September 30, 2022 | 0.215M |
| June 30, 2022 | 8.744M |
| March 31, 2022 | -0.913M |
| December 31, 2021 | 51.00M |
| September 30, 2021 | 12.58M |
| Date | Value |
|---|---|
| June 30, 2021 | 20.69M |
| March 31, 2021 | 9.943M |
| December 31, 2020 | 18.32M |
| September 30, 2020 | 20.76M |
| June 30, 2020 | -5.166M |
| March 31, 2020 | -16.31M |
| December 31, 2019 | -4.398M |
| September 30, 2019 | -10.74M |
| June 30, 2019 | -9.649M |
| March 31, 2019 | -15.67M |
| December 31, 2018 | -9.255M |
| September 30, 2018 | 3.557M |
| June 30, 2018 | -0.8534M |
| March 31, 2018 | -1.092M |
| December 31, 2017 | -1.242M |
| September 30, 2017 | -2.810M |
| June 30, 2017 | -0.1921M |
| March 31, 2017 | 0.1409M |
| December 31, 2016 | -0.1782M |
| September 30, 2016 | -0.0145M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| cbdMD, Inc. | -1.127M |
| Guardian Pharmacy Services, Inc. | 19.12M |
| Lineage Cell Therapeutics, Inc. | 4.23M |
| Tenax Therapeutics, Inc. | -16.70M |
| Heron Therapeutics, Inc. | -5.006M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 45.46M |
| Total Expenses (Quarterly) | 75.09M |
| EPS Diluted (Quarterly) | -0.254 |
| Enterprise Value | 291.18M |
| Gross Profit Margin (Quarterly) | 37.62% |
| Profit Margin (Quarterly) | -65.18% |
| Earnings Yield | -148.1% |
| Normalized Earnings Yield | -141.61 |